Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons

Timothy R. Sterling, Karla Alwood, Regina Gachuhi, William Coggin, David Blazes, William Ramses Bishai, Richard E Chaisson

Research output: Contribution to journalArticle

Abstract

Objective: To determine the rate of tuberculosis relapse among HIV-seropositive and seronegative persons treated for active tuberculosis with short-course (6-month) therapy. Design: Consecutive cohort study. Setting: City of Baltimore tuberculosis clinic. Patients: Tuberculosis patients treated between 1 January 1993 and 31 December 1996. Intervention: Patients received 2 months of isoniazid, rifampin, pyrazinamide and ethambutol followed by 4 months of isoniazid and rifampin. Main outcome measure: Passive follow-up for tuberculosis relapse was performed through September 30, 1998. Results: There were 423 cases of tuberculosis during the study period; 280 patients completed a 6-month course of therapy. Therapy was directly-observed for 94% of patients. Of those who completed therapy, 47 (17%) were HIV-seropositive, 127 (45%) were HIV-seronegative, and 106 (38%) had unknown HIV status. HIV-infected patients required more time to complete therapy (median 225 versus 205 days; P = 0.04) but converted sputum culture to negative within the same time period (median 77 versus 72 days; P = 0.43) as HIV-seronegative or unknown patients. Relapse occurred in three out of 47 (6.4%) HIV-infected patients compared to seven out of 127 (5.5%) HIV-seronegative patients (P = 1.0). Relapse rates also did not differ when HIV-seropositive patients were compared with HIV-seronegative acid patients with unknown HIV status (6.4% versus 3.0%; P = 0.38). Of the 10 patients with tuberculosis relapse, restriction fragment length polymorphism data were available for five; all five relapse isolates matched the initial isolate. Conclusions: These results support current recommendations to treat tuberculosis in HIV-infected patients with short-course (6-month) therapy.

Original languageEnglish (US)
Pages (from-to)1899-1904
Number of pages6
JournalAIDS
Volume13
Issue number14
DOIs
StatePublished - 1999

Fingerprint

Tuberculosis
HIV
Recurrence
Therapeutics
Isoniazid
Rifampin
Directly Observed Therapy
Pyrazinamide
Ethambutol
Baltimore
Sputum
Restriction Fragment Length Polymorphisms
Cohort Studies
Outcome Assessment (Health Care)
Acids

Keywords

  • HIV-1 infection
  • Lung
  • Tuberculosis
  • Tuberculosis relapse
  • Tuberculosis treatment

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. / Sterling, Timothy R.; Alwood, Karla; Gachuhi, Regina; Coggin, William; Blazes, David; Bishai, William Ramses; Chaisson, Richard E.

In: AIDS, Vol. 13, No. 14, 1999, p. 1899-1904.

Research output: Contribution to journalArticle

Sterling, Timothy R. ; Alwood, Karla ; Gachuhi, Regina ; Coggin, William ; Blazes, David ; Bishai, William Ramses ; Chaisson, Richard E. / Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. In: AIDS. 1999 ; Vol. 13, No. 14. pp. 1899-1904.
@article{28c8dd90d88c4de6a666fa853ef61bda,
title = "Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons",
abstract = "Objective: To determine the rate of tuberculosis relapse among HIV-seropositive and seronegative persons treated for active tuberculosis with short-course (6-month) therapy. Design: Consecutive cohort study. Setting: City of Baltimore tuberculosis clinic. Patients: Tuberculosis patients treated between 1 January 1993 and 31 December 1996. Intervention: Patients received 2 months of isoniazid, rifampin, pyrazinamide and ethambutol followed by 4 months of isoniazid and rifampin. Main outcome measure: Passive follow-up for tuberculosis relapse was performed through September 30, 1998. Results: There were 423 cases of tuberculosis during the study period; 280 patients completed a 6-month course of therapy. Therapy was directly-observed for 94{\%} of patients. Of those who completed therapy, 47 (17{\%}) were HIV-seropositive, 127 (45{\%}) were HIV-seronegative, and 106 (38{\%}) had unknown HIV status. HIV-infected patients required more time to complete therapy (median 225 versus 205 days; P = 0.04) but converted sputum culture to negative within the same time period (median 77 versus 72 days; P = 0.43) as HIV-seronegative or unknown patients. Relapse occurred in three out of 47 (6.4{\%}) HIV-infected patients compared to seven out of 127 (5.5{\%}) HIV-seronegative patients (P = 1.0). Relapse rates also did not differ when HIV-seropositive patients were compared with HIV-seronegative acid patients with unknown HIV status (6.4{\%} versus 3.0{\%}; P = 0.38). Of the 10 patients with tuberculosis relapse, restriction fragment length polymorphism data were available for five; all five relapse isolates matched the initial isolate. Conclusions: These results support current recommendations to treat tuberculosis in HIV-infected patients with short-course (6-month) therapy.",
keywords = "HIV-1 infection, Lung, Tuberculosis, Tuberculosis relapse, Tuberculosis treatment",
author = "Sterling, {Timothy R.} and Karla Alwood and Regina Gachuhi and William Coggin and David Blazes and Bishai, {William Ramses} and Chaisson, {Richard E}",
year = "1999",
doi = "10.1097/00002030-199910010-00012",
language = "English (US)",
volume = "13",
pages = "1899--1904",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "14",

}

TY - JOUR

T1 - Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons

AU - Sterling, Timothy R.

AU - Alwood, Karla

AU - Gachuhi, Regina

AU - Coggin, William

AU - Blazes, David

AU - Bishai, William Ramses

AU - Chaisson, Richard E

PY - 1999

Y1 - 1999

N2 - Objective: To determine the rate of tuberculosis relapse among HIV-seropositive and seronegative persons treated for active tuberculosis with short-course (6-month) therapy. Design: Consecutive cohort study. Setting: City of Baltimore tuberculosis clinic. Patients: Tuberculosis patients treated between 1 January 1993 and 31 December 1996. Intervention: Patients received 2 months of isoniazid, rifampin, pyrazinamide and ethambutol followed by 4 months of isoniazid and rifampin. Main outcome measure: Passive follow-up for tuberculosis relapse was performed through September 30, 1998. Results: There were 423 cases of tuberculosis during the study period; 280 patients completed a 6-month course of therapy. Therapy was directly-observed for 94% of patients. Of those who completed therapy, 47 (17%) were HIV-seropositive, 127 (45%) were HIV-seronegative, and 106 (38%) had unknown HIV status. HIV-infected patients required more time to complete therapy (median 225 versus 205 days; P = 0.04) but converted sputum culture to negative within the same time period (median 77 versus 72 days; P = 0.43) as HIV-seronegative or unknown patients. Relapse occurred in three out of 47 (6.4%) HIV-infected patients compared to seven out of 127 (5.5%) HIV-seronegative patients (P = 1.0). Relapse rates also did not differ when HIV-seropositive patients were compared with HIV-seronegative acid patients with unknown HIV status (6.4% versus 3.0%; P = 0.38). Of the 10 patients with tuberculosis relapse, restriction fragment length polymorphism data were available for five; all five relapse isolates matched the initial isolate. Conclusions: These results support current recommendations to treat tuberculosis in HIV-infected patients with short-course (6-month) therapy.

AB - Objective: To determine the rate of tuberculosis relapse among HIV-seropositive and seronegative persons treated for active tuberculosis with short-course (6-month) therapy. Design: Consecutive cohort study. Setting: City of Baltimore tuberculosis clinic. Patients: Tuberculosis patients treated between 1 January 1993 and 31 December 1996. Intervention: Patients received 2 months of isoniazid, rifampin, pyrazinamide and ethambutol followed by 4 months of isoniazid and rifampin. Main outcome measure: Passive follow-up for tuberculosis relapse was performed through September 30, 1998. Results: There were 423 cases of tuberculosis during the study period; 280 patients completed a 6-month course of therapy. Therapy was directly-observed for 94% of patients. Of those who completed therapy, 47 (17%) were HIV-seropositive, 127 (45%) were HIV-seronegative, and 106 (38%) had unknown HIV status. HIV-infected patients required more time to complete therapy (median 225 versus 205 days; P = 0.04) but converted sputum culture to negative within the same time period (median 77 versus 72 days; P = 0.43) as HIV-seronegative or unknown patients. Relapse occurred in three out of 47 (6.4%) HIV-infected patients compared to seven out of 127 (5.5%) HIV-seronegative patients (P = 1.0). Relapse rates also did not differ when HIV-seropositive patients were compared with HIV-seronegative acid patients with unknown HIV status (6.4% versus 3.0%; P = 0.38). Of the 10 patients with tuberculosis relapse, restriction fragment length polymorphism data were available for five; all five relapse isolates matched the initial isolate. Conclusions: These results support current recommendations to treat tuberculosis in HIV-infected patients with short-course (6-month) therapy.

KW - HIV-1 infection

KW - Lung

KW - Tuberculosis

KW - Tuberculosis relapse

KW - Tuberculosis treatment

UR - http://www.scopus.com/inward/record.url?scp=0032729851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032729851&partnerID=8YFLogxK

U2 - 10.1097/00002030-199910010-00012

DO - 10.1097/00002030-199910010-00012

M3 - Article

C2 - 10513648

AN - SCOPUS:0032729851

VL - 13

SP - 1899

EP - 1904

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 14

ER -